| Recruiting | To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma NCT06204991 | Inge Marie Svane | Phase 1 |
| Not Yet Recruiting | Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Pati NCT06780397 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma NCT06771544 | University of California, Irvine | Phase 2 |
| Recruiting | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in NCT06284590 | Philogen S.p.A. | Phase 2 |
| Active Not Recruiting | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patient NCT06551064 | Formycon AG | Phase 1 |
| Recruiting | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma NCT06295159 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775 | Miltenyi Biomedicine GmbH | N/A |
| Recruiting | Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients NCT06199713 | University of Wisconsin, Madison | — |
| Recruiting | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497 | Krystal Biotech, Inc. | Phase 1 / Phase 2 |
| Recruiting | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced NCT05655312 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Unknown | The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma NCT05827770 | Yong Chen | Phase 2 |
| Active Not Recruiting | A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Sk NCT05751928 | Biocad | Phase 3 |
| Recruiting | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial NCT05652673 | Erasmus Medical Center | N/A |
| Unknown | A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma NCT05370807 | Universitair Ziekenhuis Brussel | Phase 2 |
| Unknown | Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG NCT05467137 | University Medical Center Groningen | Phase 4 |
| Recruiting | FMT to Convert Response to Immunotherapy NCT05251389 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy NCT05732805 | Biocad | Phase 3 |
| Unknown | Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease NCT05445752 | Hospital Universitario Virgen Macarena | — |
| Recruiting | Versatile Ampification Single-Molecule Detection in Liquid Biopsy NCT05940311 | Regina Elena Cancer Institute | — |
| Active Not Recruiting | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma NCT05289193 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice NCT05402059 | MelanomaPRO, Russia | — |
| Unknown | MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] NCT06299878 | Russian Academy of Medical Sciences | — |
| Unknown | (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma NCT05767879 | Leiden University Medical Center | Phase 2 |
| Unknown | pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and t NCT05171374 | MelanomaPRO, Russia | — |
| Recruiting | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma NCT04741997 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Completed | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients Wi NCT04526899 | BioNTech SE | Phase 2 |
| Recruiting | Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma NCT04598009 | University of California, San Francisco | Phase 2 |
| Completed | Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors NCT04675346 | Oxford University Hospitals NHS Trust | — |
| Active Not Recruiting | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma NCT04207086 | Melanoma Institute Australia | Phase 2 |
| Recruiting | Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma NCT04513028 | Kelly McMasters | N/A |
| Recruiting | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients NCT04562129 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Mel NCT04330430 | The Netherlands Cancer Institute | Phase 2 |
| Active Not Recruiting | Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis NCT04305145 | Massachusetts General Hospital | Phase 2 |
| Terminated | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Co NCT04410445 | Nektar Therapeutics | Phase 3 |
| Terminated | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 NCT04455503 | Evaxion Biotech A/S | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD NCT04139902 | Diwakar Davar | Phase 2 |
| Completed | Appropriate Dosing to Optimise Personalised Cancer Treatments NCT04154163 | University of Dundee | — |
| Active Not Recruiting | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab NCT04013854 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment NCT04045691 | Pierre Fabre Pharma GmbH | — |
| Withdrawn | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS NCT04007588 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SC NCT04079166 | Scancell Ltd | Phase 2 |
| Active Not Recruiting | SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab NCT03161431 | Syntrix Biosystems, Inc. | Phase 1 |
| Completed | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma NCT03620019 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain NCT03605771 | Grupo Español Multidisciplinar de Melanoma | — |
| Unknown | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Meta NCT03161756 | Melanoma and Skin Cancer Trials Limited | Phase 1 / Phase 2 |
| Completed | A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic NCT03153085 | Takara Bio Inc. | Phase 2 |
| Unknown | Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastati NCT03190824 | Syneos Health | Phase 2 |